Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Background Dacomitinib (PF-00299804) is an oral, irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases. Methods This phase I, open-label, dose-escalation study (clinicaltrials.gov: NCT00783328) primarily evaluated the safety and tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Toshiaki, Boku, Narikazu, Murakami, Haruyasu, Naito, Tateaki, Tsuya, Asuka, Nakamura, Yukiko, Ono, Akira, Machida, Nozomu, Yamazaki, Kentaro, Watanabe, Junichiro, Ruiz-Garcia, Ana, Imai, Keiji, Ohki, Emiko, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523469/
https://www.ncbi.nlm.nih.gov/pubmed/22249430
http://dx.doi.org/10.1007/s10637-011-9789-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523469/
https://www.ncbi.nlm.nih.gov/pubmed/22249430
http://dx.doi.org/10.1007/s10637-011-9789-z

Ejemplares similares